CASI Pharmaceuticals, Inc. (CASI) Reaches $3.41 After 5.00% Down Move; The Progressive (PGR) Had 8 Bullish Analysts

December 6, 2017 - By Migdalia James

Among 18 analysts covering Progressive (NYSE:PGR), 8 have Buy rating, 3 Sell and 7 Hold. Therefore 44% are positive. Progressive had 50 analyst reports since August 6, 2015 according to SRatingsIntel. Citigroup maintained the stock with “Neutral” rating in Wednesday, October 18 report. On Thursday, May 18 the stock rating was upgraded by Deutsche Bank to “Hold”. The firm has “Equal-Weight” rating given on Wednesday, October 18 by Morgan Stanley. The rating was upgraded by Sandler O’Neill on Tuesday, March 21 to “Buy”. The stock of The Progressive Corporation (NYSE:PGR) has “Hold” rating given on Tuesday, July 18 by Wells Fargo. Wells Fargo maintained the shares of PGR in report on Wednesday, June 14 with “Hold” rating. The firm earned “Hold” rating on Wednesday, April 19 by Wells Fargo. The rating was maintained by Barclays Capital with “Underweight” on Friday, August 11. Keefe Bruyette & Woods maintained the shares of PGR in report on Wednesday, November 15 with “Buy” rating. FBR Capital maintained it with “Mkt Perform” rating and $35 target in Monday, April 3 report. See The Progressive Corporation (NYSE:PGR) latest ratings:

04/12/2017 Broker: Goldman Sachs Rating: Buy New Target: $57 Initiates Coverage On
15/11/2017 Broker: Keefe Bruyette & Woods Rating: Buy New Target: $58.0 Maintain
15/11/2017 Broker: FBR Capital Rating: Hold New Target: $46.0
17/10/2017 Broker: Keefe Bruyette & Woods Rating: Buy New Target: $56.0 Maintain
18/10/2017 Broker: Citigroup Rating: Neutral Old Target: $50 New Target: $51 Maintain
18/10/2017 Broker: Morgan Stanley Rating: Equal-Weight Old Target: $49 New Target: $51 Maintain
16/10/2017 Broker: Barclays Capital Rating: Underweight Old Target: $41 New Target: $43 Maintain
18/09/2017 Broker: Keefe Bruyette & Woods Rating: Buy New Target: $52.0 Maintain
19/09/2017 Broker: UBS Rating: Buy Old Target: $53 New Target: $52 Maintain
18/09/2017 Broker: Credit Suisse Rating: Underperform Old Target: $38 New Target: $42 Maintain

The stock of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) is a huge mover today! The stock decreased 14.75% or $0.59 during the last trading session, reaching $3.41. About 738,346 shares traded. CASI Pharmaceuticals, Inc. (NASDAQ:CASI) has declined 17.65% since December 6, 2016 and is downtrending. It has underperformed by 34.35% the S&P500.The move comes after 9 months negative chart setup for the $221.88M company. It was reported on Dec, 6 by Barchart.com. We have $3.24 PT which if reached, will make NASDAQ:CASI worth $11.09M less.

CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China. The company has market cap of $221.88 million. The Company’s lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma. It currently has negative earnings. The companyÂ’s late-stage clinical drug candidates, including MARQIBO, a microtubule inhibitor to treat adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-hodgkinÂ’s lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkinÂ’s lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma.

Among 2 analysts covering CASI Pharmaceuticals Inc (NASDAQ:CASI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CASI Pharmaceuticals Inc had 4 analyst reports since October 29, 2015 according to SRatingsIntel. The rating was initiated by H.C. Wainwright with “Buy” on Thursday, October 29. Maxim Group initiated the shares of CASI in report on Thursday, September 22 with “Buy” rating. The firm has “Buy” rating by Maxim Group given on Monday, August 14.

Investors sentiment increased to 1.67 in 2017 Q2. Its up 0.92, from 0.75 in 2017Q1. It is positive, as 0 investors sold CASI Pharmaceuticals, Inc. shares while 6 reduced holdings. 5 funds opened positions while 5 raised stakes. 2.29 million shares or 2.19% less from 2.34 million shares in 2017Q1 were reported. Geode Mgmt Limited Liability Corporation holds 38,315 shares. Manatuck Hill Lc invested 0.01% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Moreover, Wells Fargo And Com Mn has 0% invested in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 68 shares. 2 were reported by Next Gp Incorporated. Kansas-based Creative Planning has invested 0% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Renaissance Tech Ltd Liability Co holds 0% or 106,200 shares in its portfolio. Everett Harris And Commerce Ca holds 0% or 10,002 shares. Focused Wealth Management Incorporated invested 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Moors & Cabot Inc invested in 26,053 shares or 0% of the stock. Moreover, Raymond James Fincl Svcs has 0% invested in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Wellington Shields Cap Mgmt Ltd Liability Corp has 726,069 shares. Morgan Stanley stated it has 1,133 shares. California-based California Pub Employees Retirement Systems has invested 0% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Wellington Shields And Ltd Liability holds 0.18% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 505,474 shares. Susquehanna Grp Llp, Pennsylvania-based fund reported 17,850 shares.

The stock increased 0.15% or $0.08 during the last trading session, reaching $54.33. About 323,276 shares traded. The Progressive Corporation (NYSE:PGR) has risen 26.23% since December 6, 2016 and is uptrending. It has outperformed by 9.53% the S&P500.

Since June 16, 2017, it had 0 insider purchases, and 2 selling transactions for $2.46 million activity. $2.23 million worth of The Progressive Corporation (NYSE:PGR) shares were sold by CODY WILLIAM M. $223,695 worth of The Progressive Corporation (NYSE:PGR) shares were sold by Sieger Michael D.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com